() Diagnostic IV 351 Aim: To establish trimester-specific thyroid TSH concentrations showed slightly increasing trial function reference intervals throughout median centile throughout gestation (. Free pregnancy, and to examine the prevalence thyroxine (T4) and T3 decreased throughout of thyroid autoimmunity in otherwise euthyroid gestation. Derived reference ranges (2.5th to women. 97.5th percentiles) for TSH exclusive of TPO positive women were: Setting: Cork University Hospital, Ireland Week 12: 0.2–3.0 Population: Pregnant women (median age 30) attending a large, tertiary referral Week 14–16: 0.2–3.1 maternity hospital. Patients with known thyroid Week 18–22: 0.3–3.1 disorders, autoimmune disease, recurrent Week 24: 0.4–3.1 miscarriage, hyperemesis gravidarum and Week 26–28: 0.4–3.2 pre-eclampsia were excluded. Week 30–32: 0.5–3.2 Measurements: TFTs were analysed in the CUH Week 34: 0.5–3.3 biochemistry laboratory trial Roche Modular E170 electrochemiluminescent immunoassay. Week 36–38: 0.6–3.3 Trimester-specific reference ranges (2.5th, Week 40: 0.7–3.3 50th and 97.5th centiles) were calculated.
() Diagnostic IV 351 Aim: To establish trimester-specific thyroid function reference intervals throughout pregnancy, and to examine the prevalence of thyroid autoimmunity in otherwise euthyroid women. Setting: Cork University Hospital, Ireland Population: Pregnant women (median age 30) attending a large, tertiary referral maternity hospital. Patients with known thyroid disorders, autoimmune disease, recurrent miscarriage, hyperemesis gravidarum and pre-eclampsia were excluded. Measurements: TFTs were analysed in the CUH biochemistry laboratory Roche Modular E170 electrochemiluminescent immunoassay. Trimester-specific reference ranges (2.5th, 50th and 97.5th centiles) were calculated. TSH concentrations showed slightly increasing median centile throughout gestation (. Free thyroxine (T4) and T3 decreased throughout gestation. Derived reference ranges (2.5th to 97.5th percentiles) for TSH exclusive of TPO positive women were: Week 12: 0.2–3.0 Week 14–16: 0.2–3.1 Week 18–22: 0.3–3.1 Week 24: 0.4–3.1 Week 26–28: 0.4–3.2 Week 30–32: 0.5–3.2 Week 34: 0.5–3.3 Week 36–38: 0.6–3.3 Week 40: 0.7–3.3 trial trial
Thyroid%20dysfunction%20evidence%20evaluation%2016May17.docx